Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas, Inc. will present novel biomarker data from a Phase 1 clinical trial of its investigational drug, ARV-102, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 is a PROTAC LRRK2 degrader designed to treat Parkinson's disease. The data will be shared in both oral and e-poster presentations, detailing oculomotor and biomarker findings from the study.
Arvinas (NASDAQ:ARVN) Shares Climb 6.3% - What's Next?
Arvinas (NASDAQ:ARVN) shares rose 6.3% during midday trading on Wednesday, though trading volume was significantly below average. The company recently reported a strong quarterly beat with revenue up 1,014.7% year over year and EPS of $2.58. Analysts maintain a "Hold" rating with a consensus price target of $14.55.
252,939 Shares in Arvinas, Inc. $ARVN Acquired by Bank of America Corp DE
Bank of America Corp DE has acquired 252,939 shares of Arvinas, Inc. (NASDAQ:ARVN), valued at approximately $2.1 million, representing 0.39% of the company. Institutional investors now own 95.19% of Arvinas. Analysts currently have a "Hold" rating on the stock with an average price target of $14.55, despite the company reporting strong quarterly revenue and earnings that significantly exceeded estimates.
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas, Inc. announced an inducement grant to a newly hired employee, consisting of an option to purchase 64,766 shares of common stock and 42,388 restricted stock units. These awards, granted on September 28, 2026, are made in accordance with Nasdaq Listing Rule 5635(c)(4) and are not part of Arvinas’ stock incentive plan. The grants are subject to vesting over four years, contingent on continued employment.
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas, Inc., a clinical-stage biotechnology company, announced the grant of an option to purchase 64,766 shares of common stock and 42,388 restricted stock units to a new employee. These awards were granted on September 28, 2026, under Nasdaq Listing Rule 5635(c)(4) and not through the company's stock incentive plan. The awards will vest over four years, subject to the employee's continued service.
Press Release: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas, Inc. announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. The grant consists of a stock option to purchase 25,000 shares of common stock, vesting over four years. This action aims to attract and retain key talent within the company.
Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial
Arvinas, Inc. has initiated a Phase I/II trial for ARV-6723, an oral PROTAC degrader targeting HPK1, marking its entry into immuno-oncology. This drug aims to degrade the HPK1 protein, a negative regulator of immune activation, and is being evaluated as both monotherapy and in combination with pembrolizumab for advanced solid tumors. ARV-6723 is the first HPK1 PROTAC degrader to enter clinical development in the US, expanding Arvinas's PROTAC pipeline.
Arvinas doses first patient in ARV-6723 cancer trial
Arvinas Inc. (NASDAQ:ARVN) has announced the dosing of the first patient in its Phase 1/2 clinical trial for ARV-6723, an oral drug targeting hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. This marks Arvinas' first immuno-oncology clinical candidate and the first HPK1 PROTAC degrader to enter clinical trials in the U.S. Preclinical studies showed ARV-6723's ability to degrade HPK1, enhance immune activity, and demonstrate antitumor effects both as a monotherapy and in combination with an immune checkpoint inhibitor.
Arvinas doses first patient in ARV-6723 cancer trial By Investing.com
Arvinas Inc. has announced the dosing of the first patient in its Phase 1/2 clinical trial for ARV-6723, an oral drug targeting advanced solid tumors. This drug is the first HPK1 PROTAC degrader to enter clinical trials in the U.S. and aims to degrade hematopoietic progenitor kinase 1 (HPK1) to enhance immune activity. Preclinical studies showed ARV-6723's effectiveness as a single agent and in combination with an immune checkpoint inhibitor.
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical
Arvinas, Inc. has dosed the first patient in its Phase 1/2 clinical trial for ARV-6723, an investigational oral PROTAC designed to degrade HPK1 in advanced solid tumors. This marks Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the U.S. Preclinical studies showed ARV-6723's potential to enhance immune activity and demonstrate antitumor activity, including in models resistant to immune checkpoint inhibitors.
A cancer drug designed to remove a protein that limits immune activity enters human testing.
Arvinas (ARVN) has initiated a Phase 1/2 clinical trial for ARV-6723, its first immuno-oncology candidate, designed to degrade the HPK1 protein which restricts immune activation. The oral drug will be evaluated for safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in adults with advanced solid tumors, initially as monotherapy and later in combination with pembrolizumab. Preclinical studies showed ARV-6723 effectively enhanced immune activity and demonstrated antitumor effects, including in models resistant to current immune checkpoint inhibitors.
Arvinas Q2 2026 Earnings Call Transcript
Arvinas Inc. reported significant progress in Q2 2026, including the FDA approval of its PROTAC degrader Vepanu, an out-licensing agreement with Rigel Pharmaceuticals, and a strategic decision to seek a partner for its KRAS G12D program. The company is now focusing on advancing its Phase 1 clinical programs for ARV393 (BCL6 degradation), ARV027 (polyglutamine repeat androgen receptors), and ARV102 (LRRK2 degradation). Arvinas ended the quarter with $567.9 million in cash, reported $249.7 million in total revenue, and expects its cash runway to last into the second half of 2028.
Arvinas (NASDAQ: ARVN) director plans stock sale under SEC resale rule
Arvinas director Sunil Agarwal plans to sell up to 23,105 shares of common stock under SEC Rule 144. The shares, valued at $196,242.32, are from a stock option exercise and are scheduled for sale on September 22, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ. This filing indicates a neutral impact and sentiment, detailing the transaction specifics and providing definitions for relevant financial terms.
Former Arvinas (NASDAQ: ARVN) officer plans new stock sale
Former Arvinas officer Noah C. Berkowitz has filed a Rule 144 notice to sell 37,200 shares of Arvinas common stock, valued at $328,914.96. This planned sale, set for September 9, 2026, follows the exercise of options under a registered plan. Berkowitz has also reported previous sales of Arvinas common stock in July, August, and early September 2026.
The Technical Signals Behind (ARVN) That Institutions Follow
This article analyzes Arvinas Inc. (NASDAQ: ARVN) using AI models to provide technical signals for institutional trading. It highlights strong near and mid-term sentiment, potential resistance testing, and a weak long-term outlook. The report offers specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies, emphasizing a significant risk-reward short setup.
142,214 Shares in Arvinas, Inc. $ARVN Purchased by GSA Capital Partners LLP
GSA Capital Partners LLP recently purchased 142,214 shares of Arvinas, Inc. (NASDAQ:ARVN) valued at approximately $1.18 million, as disclosed in their latest 13F filing. Other institutional investors also adjusted their holdings, with several significantly increasing their stakes. Arvinas recently reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, and several analysts have updated their ratings and price targets for the stock.
D. E. Shaw adjusts Arvinas (ARVN) stake as one entity falls below 5%
D. E. Shaw & Co. has adjusted its ownership in Arvinas, Inc. (ARVN), with D. E. Shaw & Co., L.P. and David E. Shaw each reporting a 5.4% beneficial ownership. Notably, D. E. Shaw & Co., L.L.C. has fallen below the 5% threshold, now holding 4.7% of the common stock. All reported beneficial ownership involves shared voting and dispositive powers through affiliated investment vehicles.
Enterprise value to EBITDA forward of Arvinas, Inc. – NASDAQ:ARVN
The article focuses on the enterprise value to EBITDA forward of Arvinas, Inc. (NASDAQ: ARVN), providing financial information and market data for the company. It appears to be a financial data page from TradingView, indicating that the market was closed with no trades at the time of viewing.
ARVN Maintains by Evercore ISI Group -- Price Target Lowered to $14.00
Evercore ISI Group has maintained an Outperform rating for Arvinas (ARVN) but lowered its price target from $19.00 to $14.00, reflecting a cautious outlook. Despite being significantly undervalued by GuruFocus's GF Value™ at $31.53 versus a current price of $8.95, the company faces financial challenges, high P/E ratios, and negative insider sentiment. Investors are advised to exercise caution and conduct thorough research due to the discrepancy between potential undervaluation and current financial indicators.
ARVN Maintained by Citigroup -- Price Target Lowered to $21.00
Citigroup has maintained a Buy rating for Arvinas (ARVN) but lowered its price target from $24.00 to $21.00, reflecting a 12.50% decrease. Despite this adjustment and concerns over profitability and insider selling, GuruFocus indicates ARVN is significantly undervalued with a GF Value™ of $31.53 against its current price of $9.01. The company shows strong growth potential but faces valuation and insider confidence challenges.
Arvinas, Inc. Stock 12‑Month Price Target Cut to $13.93, Implies 59% Upside
Arvinas, Inc.'s average 12-month price target has been lowered from $14.23 to $13.93 by 14 analysts, with forecasts ranging from $6 to $21 per share. This new target suggests a potential upside of approximately 59% from the Aug. 7 closing price. The consensus rating among 16 analysts remains "Buy," comprising 7 Buys, 8 Holds, and 1 Sell recommendation.
Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating
Morgan Stanley has lowered its price target for Arvinas (ARVN) to $10 from $11, while maintaining an Equalweight rating on the stock. This adjustment comes amidst other analyst activities concerning Arvinas, including Wedbush also adjusting its price target. The company, a clinical-stage biotechnology firm, continues to develop protein degradation therapies.
Arvinas (Nasdaq: ARVN) turns Q2 profit as VEPPANU becomes first FDA-approved PROTAC
Arvinas, Inc. (Nasdaq: ARVN) reported a significant turnaround in its Q2 2026 financials, posting a net income of $169.4 million driven by the FDA approval of VEPPANU, the first PROTAC degrader, and strategic licensing agreements. The company's revenue surged to $249.7 million, and its cash reserves are projected to fund operations into the second half of 2028, while it continues to advance several other PROTAC candidates through clinical trials.
Precision Trading with Arvinas Inc. (ARVN) Risk Zones
This article provides a detailed AI-driven analysis for Arvinas Inc. (ARVN), highlighting potential trading strategies based on sentiment and risk zones. It outlines long, breakout, and short strategies with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels to assist in precision trading.
Precision Trading with Arvinas Inc. (ARVN) Risk Zones
This article provides a detailed analysis of Arvinas Inc. (NASDAQ: ARVN) focusing on precision trading strategies generated by AI models. It highlights a significant risk-reward setup with a potential 31.0% gain versus 0.3% risk, along with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) significantly surpassed Q2 earnings and revenue estimates, reporting $2.58 per share against an expected loss of $0.24, and revenues of $249.7 million, exceeding estimates by 562.56%. Despite this strong performance, the stock has underperformed the S&P 500 year-to-date, with its future movement dependent on management's commentary and ongoing earnings estimate revisions. The company currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Price to book forward of Arvinas, Inc. – NASDAQ:ARVN
This article provides a financial metric, "Price to book forward," for Arvinas, Inc. (NASDAQ:ARVN). It appears to be a stub or a data point from a financial platform, showing the company's ticker, market, and a period value, but without further elaboration or detailed financial data. The content primarily consists of navigation and platform information from TradingView.
Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen
Wall Street Zen has upgraded Arvinas (NASDAQ:ARVN) from a "Sell" to a "Hold" rating. This upgrade comes despite mixed analyst sentiments and a forecast for a full-year loss, following a significant quarterly earnings beat where Arvinas reported $2.58 EPS against expected a $0.37 loss and revenue exceeding expectations by over 1,000%. The company's stock, however, remains below its 52-week high, trading at $8.75.
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Arvinas Inc (ARVN), indicating its current earnings forecast score, average price target, and analyst ratings. Based on 17 analysts, the stock has a "Buy" trend with a target price of $14.00, suggesting a potential upside of 61.90%. The article also includes expected revenue and EPS for upcoming quarters and highlights past performance compared to market expectations.
Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology
Arvinas recently released a corporate presentation that highlights its PROTAC degrader pipeline, focusing on advancements in oncology and neurology. Key updates include the FDA clearance of VEPPANU for advanced breast cancer and the out-licensing of luxdegalutamide to Novartis, generating over $800 million in non-dilutive cash and extending Arvinas's cash runway into the second half of 2028. Novartis is currently conducting three Phase 2 trials for luxdegalutamide in metastatic prostate cancer settings.
Arvinas Inc (ARVN) Stock News Today
This article provides a current snapshot of Arvinas Inc (ARVN) stock information. It includes the latest stock price, market capitalization, and a note indicating that more news, earnings, and analyst ratings are coming soon. The page serves as a placeholder for future updates on ARVN.
Enterprise value to revenue forward of Arvinas, Inc. – NASDAQ:ARVN
This article provides a financial snapshot for Arvinas, Inc. (NASDAQ: ARVN), focusing on its enterprise value to revenue forward. It appears to be a financial data point from TradingView, showing the period, value, and change for this specific metric. The content itself is very minimal, presenting only the metric's title and placeholders for its values.
Arvinas (NASDAQ:ARVN) Trading Down 7.8% on Analyst Downgrade
Arvinas (NASDAQ:ARVN) shares dropped 7.8% after Wells Fargo downgraded the stock from "overweight" to "equal weight." Despite this, the company reported a significant second-quarter beat with EPS of $2.58 and revenue of $249.7 million, largely due to licensing and milestone activities. Arvinas also received approval for VEPPANU, its first PROTAC protein degrader, and anticipates clinical data from three Phase 1 programs within the next year.
Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit
Arvinas (ARVN) reported a significant turnaround in Q2 2026, driven by a surge in licensing revenue from its collaboration with Pfizer and the Rigel license agreement, leading to a profit of $2.58 diluted EPS. The company's revenue reached $249.7 million, up from $22.4 million a year earlier, and operating expenses decreased, primarily due to lower R&D spending. Despite the accounting-driven profit, Arvinas experienced cash consumption in operations during the first half of 2026, though its cash reserves are projected to fund operations into the second half of 2028.
Arvinas (ARVN) Stock Jumps As Profit Windfall Sparks Durability Debate
Arvinas (ARVN) stock surged 11.7% after reporting Q2 earnings, driven by a significant profit from licensing and collaboration revenue. Despite this windfall, concerns remain about the durability of its profit, as much of it was from one-off payments rather than recurring income, leading to a debate about the long-term stability of its milestone-heavy business model. The company's pipeline is becoming more concentrated, and key readouts for future programs are not expected until beyond 2026.
Arvinas (ARVN) holder Noah C. Berkowitz plans sale of 30,000 shares
Noah C. Berkowitz, a shareholder of Arvinas (ARVN), has filed notice to sell 30,000 shares of common stock for an approximate aggregate price of $264,000 through Morgan Stanley. The filing also disclosed a previous sale of 24,000 shares on July 9, 2026, for $201,528. Additionally, two tranches of restricted stock, totaling 30,000 shares, are scheduled to vest in May and July 2026 as compensation for services.
Arvinas (NASDAQ: ARVN) posts $169.4M profit on VEPPANU and Rigel deals
Arvinas (NASDAQ: ARVN) reported a significant financial turnaround in Q2 2026, posting a net income of $169.4 million and revenue of $249.7 million, compared to a net loss of $61.2 million and $22.4 million revenue in Q2 2025. This profitability was largely driven by collaboration and licensing revenues related to VEPPANU (vepdegestrant), including deals with Pfizer and Rigel Pharmaceuticals. The company's cash reserves stood at $567.9 million, projected to fund operations into the second half of 2028, and they continue to advance multiple PROTAC degrader programs in oncology and neurology.
ARVINAS, INC. 2026: Revenue $249.7M, EPS $2.58— 10-Q Summary
ARVINAS, INC. reported significant financial growth in 2026, with revenue reaching $249.7M and diluted EPS at $2.58, largely driven by licensing and milestone recognition. Key business highlights include FDA approval for VEPPANU and its out-license to Rigel, leading to substantial upfront and milestone payments. The company also advanced multiple clinical programs and optimized operations through workforce reductions.
Arvinas, Inc. Stock 12‑Month Price Target Cut to $14.85, Implies 84% Upside
Arvinas, Inc.'s average 12-month price target has been lowered from $15.08 to $14.85 by 13 analysts, with individual forecasts ranging from $6 to $24. This updated target suggests an 84% potential upside based on the Aug. 3 closing price. Despite the price target cut, the consensus rating from 15 analysts remains a "Buy," with 7 Buys, 7 Holds, and 1 Sell recommendation.
BTIG reiterates Arvinas stock Buy rating on pipeline execution
BTIG reiterated a Buy rating and an $18.00 price target on Arvinas Inc. (NASDAQ:ARVN) following the company's strong second-quarter earnings report. Arvinas reported significant GAAP revenue of $249.7 million and a cash position of $567.9 million, providing runway into the second half of 2028. The company is advancing several clinical programs with key data readouts and trial initiations expected in late 2026 and 2027.
Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating
Wedbush has increased its price target for Arvinas (ARVN) to $12 from $11, while maintaining a Neutral rating on the stock. This adjustment comes as Arvinas continues to advance its PROTAC protein degrader platform and multiple investigational drugs through clinical development.
Arvinas (NASDAQ:ARVN) Trading 14.8% Higher Following Better-Than-Expected Earnings
Arvinas (NASDAQ:ARVN) saw its shares surge 14.8% after reporting better-than-expected quarterly earnings and revenue. The company beat consensus EPS estimates by $2.95 and reported a 1,014.7% year-over-year revenue increase. Despite mixed analyst ratings, the stock holds a consensus Hold rating with a target price of $15.42.
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) reported Q2 earnings of $2.58 per share, significantly surpassing the Zacks Consensus Estimate of a $0.24 loss and year-ago loss of $0.84. The company's revenue reached $249.7 million, beating estimates by 562.56% and showing substantial growth from $22.4 million a year prior. Despite strong Q2 results, Arvinas shares have declined 32% year-to-date, contrasting with the S&P 500's 11% gain.
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) reported Q2 earnings of $2.58 per share, significantly beating the Zacks Consensus Estimate of a $0.24 loss per share, and revenues of $249.7 million, exceeding estimates by 562.56%. Despite this strong performance, the stock has underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #3 (Hold). The company's future performance will depend on management's outlook and industry trends.
Transcript: Arvinas Q2 2026 Earnings Conference Call
Arvinas (NASDAQ: ARVN) reported its Q2 2026 earnings, highlighting significant strategic milestones including FDA approval of their first PROTAC degrader, Vepanu, and an out-licensing deal with Rigel Pharmaceuticals. The company announced $249.7 million in revenue for the quarter and a strong cash position of $567.9 million, projecting financial stability through 2028. Arvinas plans to advance its oncology and neurology pipeline, with key clinical data expected in the next 12 months for ARV393 (BCL6 degrader), ARV027 (SBMA), and ARV102 (LRRK2 degrader for PSP/PD).
FDA approves first PROTAC therapy as Arvinas licenses VEPPANU
Arvinas (Nasdaq: ARVN) reported strong Q2 2026 financial results, with revenue soaring to $249.7 million due to the FDA approval and out-licensing of VEPPANU, the first-ever PROTAC degrader. VEPPANU, approved for ER+/HER2-, ESR1-mutated advanced breast cancer, was licensed to Rigel Pharmaceuticals for global development and commercialization. The company also provided updates on its diverse pipeline of PROTAC programs, including ARV-393, ARV-102, ARV-027, and the initiation of a new immuno-oncology trial for ARV-6723, and confirmed a cash runway into the second half of 2028.
Arvinas reports $249.7M Q2 revenue, $169.4M net income and guidance into H2 2028
Arvinas reported strong financial results for Q2 2026, with revenue of $249.7 million and net income of $169.4 million, largely due to collaboration and licensing agreements. The company announced that its cash reserves of $567.9 million are sufficient to fund operations into the second half of 2028. Key business highlights include the FDA approval of VEPPANU and its subsequent licensing to Rigel, along with significant progress in its clinical pipeline with several upcoming data milestones.
Earnings To Watch: Arvinas Inc (ARVN) Q2 2026 -- GF Value Sees 34% Upside
Arvinas Inc (ARVN) is preparing to release its Q2 2026 earnings on August 4, 2026, with analysts forecasting $32.54 million in revenue and an EPS of -$0.44. Despite missing previous quarter's estimates, the GF Value suggests a 34.37% upside from its current price, and brokerage firms rate it as "Outperform." Revenue and earnings estimates for the full year 2026 have seen adjustments in the past 90 days.
Price to sales forward of Arvinas, Inc. – NASDAQ:ARVN
This article provides financial information for Arvinas, Inc. (NASDAQ: ARVN), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and no trades were made. The content is part of a larger financial data platform.
Arvinas Inc (ARVN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Arvinas Inc (ARVN), noting its current valuation score of 6.66 within the Biotechnology & Medical Research industry. It details the company's current P/E ratio, contrasting it with recent highs and lows. The report also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by Arvinas Inc.
